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osting by EAbstract Background: The incidence of cardiovascular disease in patients with type 2 diabetes
mellitus is approximately twice as high as in the non-diabetic population.
Aim: To investigate the hypoglycemic and hypocholesterolemic effects of Daﬂon 500 mg (DF)
administration together with its tolerability and efﬁcacy in reducing the cardiovascular metabolic
risk factors in female patients with type 2 diabetes.
Methods: In a well-adequate controlled single-blinded randomized parallel design the tolerability
and the efﬁcacy of Daﬂon (500 mg) either alone or with oral hypoglycemic, twice daily for 45 days,
was studied in 36 female patients with type 2 diabetes.
Results: None of the patients in the studied groups were reported to have any adverse events
throughout the treatment period (45 days), liver and kidney function tests were within normal limits
and there was no signiﬁcant difference between the pre-treatment (day 0) and post-treatment (day
45) values. Female patients receiving Daﬂon either alone or with oral hypoglycemic showed sig-
niﬁcant decrease in serum glucose; fructosamine; total cholesterol; LDL–cholesterol; triglycerides;
malondialdehydes (as index of lipid peroxidation) and C-reactive protein (CRB) levels along with
increase in the levels of nitric oxide and blood glutathione.
Conclusion: This study has shown that Daﬂon (500 mg, twice daily for 45 days) is helpful in
reducing glucose level and the risk of cardiovascular disease in type 2 diabetic patients.
Recommendation: Further clinical trials are essential for strengthening the evidence base on the role
of this drug in the cardiovascular risk in diabetic patients.
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ity. All rights reserved. Peer-
d University.
lsevier1. Introduction
Patients with type 2 diabetes exhibit a number of risk factors
for serious co-morbidities (Adler et al., 2002), for this reason,
it is important to focus on the metabolic component of the risk
that may lead to cardio-vascular event. Under laying the con-
cept of this metabolic (cardiometabolic) risk is the presence of
hyperglycemia. In patients with type 2 diabetes previous
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degree of hyperglycemia and increased risk of microvascular
complications, myocardial infraction, stroke, macrovascular
mortality and all cause mortality (Stratton et al., 2000). The
presence of plasma lipid abnormalities, which include reduc-
tion in high density lipoprotein cholesterol (HDL–C), an alter-
ation in the structure and concentration of the low density
lipoprotein cholesterol (LDL–C) and increased triglycerides
is associated with a particular high risk of cardiovascular com-
plication (Krauss, 2004). In addition, several experimental,
epidemiologic and clinical studies support the notation that
oxidative stress plays a signiﬁcant role in type 2 diabetes mel-
litus and in the development of cardiovascular diseases (Jacob
and Burri, 1996). Reactive oxygen species (ROS), which con-
vert Ox-LDL into highly oxidized LDL, which is, in turn, ta-
ken up by macrophages to form foam cells (Channon, 2002).
Foam cells combine with leukocytes to become the fatty
streak, which is converted to ﬁbrous plaque that will protrude
into the arterial lumen, calciﬁed, yielding a ﬁbrous cap that
surrounds a lipid-rich core. In acute coronary syndromes
(e.g., myocardial infraction), when ﬁbrous plaques rupture,
the formation and release of thrombi may ultimately occlude
vessels (Madamanchi et al., 2005). It is also reported that
ROS production was signiﬁcantly higher in unstable versus
stable angina pectoris, which suggests that ROS might also
modulate plaque stability (Channon, 2002).
Impairment in the bioavailability of nitric oxide (NO) re-
sults in compromised vasodilatation with subsequent increase
the cardiovascular risk (Endemann and Schiffrin, 2004). As
such, glucose; lipid and oxidative stress lowering therapy with
increase in NO (nitrite/nitrate) level may held to reduce cardio-
vascular risk in these patients.
In our study, we measure serum C- reactive protein (CRP)
as a marker for increased risk of cardiovascular disease. CRP
is released in response to inﬂammatory markers present within
atherosclerotic plaques. Several studies have shown a correla-
tion between elevated levels of CRP and cardiovascular events
in patients with coronary heart disease, independent of serum
lipid concentrations and may be a stronger predictor of cardio-
vascular disease than LDL cholesterol (Ridker et al., 2004).
Previous reports stated that CRP is one of the strongest inde-
pendent predictors of future cardiovascular events both in pa-
tients with CVD and in healthy subjects (Le Melle´do et al.,
2004). The American Heart Association recommends obtain-
ing CRP levels in patients at intermediate risk of a cardiovas-
cular event. In these patients an elevated CRP (>3 mg/L) is
considered to confer high risk (Pearson et al., 2003).
Daﬂon (micronized puriﬁed ﬂavonoid fraction of Ruta-
ceae aurantiae, consisting of 90% diosmin and 10% hesperi-
din) has been used in clinical practice to treat a variety of
lymphoedemas, such as post haemorrhoids (Cospite, 1994),
post-phlebitic syndrome, and idiopathic cyclic oedema syn-
drome (Pecking, 1995), radical mastectomy oedema (Pecking
et al., 1997), chronic venous insufﬁciency (Le Deyehat et al.,
1997) and varicose ulcers (Guilhou et al., 1997).
Finally, the aim of this study is to evaluate the hypoglyce-
mic and hypocholesterolemic effects of Daﬂon 500 mg (DF)
in type 2 diabetic female patients. To date, no clinical trials
have been conducted to assess the suitability of this drug in
decreasing the risk of cardiovascular in type 2 diabetes. In this
study, we are presenting our observations on the tolerability
and efﬁcacy of Daﬂon (500 mg, twice a day for 45 days) inreducing cardiovascular metabolic risk factors in patients with
type 2 diabetes.
2. Experimental and methods
2.1. Patients and methods
2.1.1. Chemicals
All chemicals used in this study were of analytically pure grade
from Sigma–Aldrich (GERMANY) or from purest grade
available.
Daﬂon 500 mg tablet was kindly supplied by Servier,
France.
2.1.2. Study design and treatment regimen
Thirty-six female patients of type 2 diabetes, between the
ages of 40.00–69.00 years (mean of 50.67 ± 3.01), who had
signed a written informed consent of the study, were admit-
ted to National Institute of Diabetes in Egypt, for a period
of four days and randomly allocated into two drug groups:
Group A received Daﬂon (500 mg) + oral hypoglycemic
twice a day for 45 days, and
Group B received Daﬂon (500 mg) twice a day for 45
days.
In addition, 18 female normal volunteers were participated
in this study, and served as normal control between the ages of
36.00–47.00 years (mean of 41.667 ± 5.129).
The appropriate drug regimen was administered to the pa-
tients twice daily (morning and evening doses) from day 1 to
day 3 (three days excluding day 0, i.e. day of admission) of
hospitalization, under the direct supervision of the medical
team. Patients were discharged on the morning of day 4 with
a pack of the appropriate drug capsules (for the next 7 days:
to complete the treatment up to day 10). The patients were
educated and instructed by the physician and the researchers
to comply with the dosage schedule. Thereafter, patients were
requested to attend weekly to the institute to allow measure-
ment of blood glucose level and to receive the drugs needed
for the next week.
All patients were clinically monitored for any adverse reac-
tions (such as abdominal pain, nausea, vomiting, chest pain,
diarrhea, fever, headache, myalgia and chills) at 8 h intervals
for ﬁrst 24 h and thereafter every 24 h for further two days (un-
til the end of day 3). All systemic reactions, if any, were re-
corded in a pre-designed form. Laboratory investigations on
biochemistry parameters (blood urea, creatinine, alanine trans-
aminase (ALT), aspartate transaminase (AST), alkaline phos-
phatase (AST) were assessed on day 0, (pre-treatment), and on
completion of treatment (day 45).
2.1.3. Patients’ data collection and follow-up
The following information would be collected; demographic
data including; age, occupation, medication history including;
past and current medication (prescribed and OTC) drug aller-
gies and adverse effects, disease history and its complications
(if present), family history, social habits and subjective param-
eters. Patients were given the Daﬂon (DF) tablets with
administration instructions, following-up was performed
through weekly meeting with those patients in the national
institute of diabetes, besides their telephones and home address
were registered for more following-up procedures to ensure
Evaluation of clinical activity and safety of Daﬂon 500 mg in type 2 diabetic female patients 201their compliance and adherence to the DF tablets 500 mg dos-
age regimen (twice daily) and to document any subjective
improvement or dete-riorations.
(i) Inclusion criteria
(1) Female type 2 diabetic patients.
(2) Disease history not more than 8 years.
(3) Patients who comply with the regular visits to the
national institute of diabetes.
(4) Patients with moderate hyperglycemia.
(ii) Exclusion criteria
(1) Type 1 diabetic patients.
(2) Disease history more than 8 years.
(3) Patients not comply with the regular visits to the
national institute of diabetes.
(4) Patients with severe hyperglycemia.
(5) Patients suffering from acute or chronic renal diseases.
(6) Patients with known liver disease(s).
(7) Patients with coronary artery diseases.
(8) Patients with a history of hyper- and/or hypo-glycemic
coma.
(9) Patients with severe diabetic complications.
(10) Illiterate patients.
2.1.4. Patients’ evaluation and biochemical determinations
Serum activities of AST, ALT and ALP were determined by
using the reagents of kits supplied by Randox (United King-
dom). Serum concentration of urea and creatinine were deter-
mined by using the reagents of kits supplied by Bayer Health
Care (France).
Fasting serum glucose level was determined according to
the method of Burrin and Price (1985) by using the reagents
of kits supplied by Sera-Pak of Bayer (France). Serum fructos-
amine level was determined kinetically according to the meth-
od of Schleicher et al. (1990) by using the kit supplied by
Quimica Clinica Aplicada (Spain). Glycosylated haemoglobin
(HbA1c) was determined as percent of HbA1c in human whole
blood using ion-exchange high-performance liquid chromatog-
raphy (HPLC) technique according to method of Little et al.
(1983) by using the Kit supplied from Bio-Rad D-10 (France)
using the Bio-Rad D-10 hemoglobin testing system.
Serum total cholesterol was determined enzymatically
according to the method of Allain et al. (1974) using Biocon
kit (Germany), after 15 h fasting of the patients. Serum
HDL–cholesterol was determined according to the method
of Friedewald et al. (1972) and serum LDL–cholesterol was
calculated from the equation developed by Friedewald et al.
(1972). Serum triglyceride was determined enzymatically
according to the method of Wahlefeld and Bergmeyer (1974)
by using the reagents of kit supplied by Biocon (Germany).
The blood reduced glutathione (GSH) and protein thiols
(PSH) levels were determined colorimetrically according to
the methods of Beutler et al. (1963) and Koster et al. (1986).
Malondialdehyde (MDA) as an index of lipid peroxidation
was assessed colorimetrically according to the method of
Mihara and Uchiyama (1978). A high correlation between
endogenous nitric oxide (NO) production and nitrite/nitrate
level in plasma and serum has been established. Therefore,
measurement of these levels provides a reliable and quantita-tive estimate of NO output in vivo (Granger et al., 1996). In
our study, levels of serum nitrite and nitrate were estimated
as an index for NO levels according to Miranda et al. (2001).
C-reactive protein (CRP) was determined by ELISA tech-
nique according to the method of Gewurz et al. (1982) using
the kit supplied from Diamed Eurogen (Belgium). Statistical
analysis of the results are expressed as mean ± SEM. The data
were analyzed by ANOVA followed by Tukey test and the sig-
niﬁcant level was chosen at P<0.05.
3. Results
3.1. Patients’ data collection
The patients’ age ranges from 40.00 to 69.00 years (mean of
50.67 ± 3.01), weight ranges from 63.00 to 95.00 kg (mean
of 84.60 ± 5.63), all of the patients were house-wives, disease
history ranges from 0.20 to 7.00 years (mean of 3.08 ± 0.87).
Concerning the medication history it was found that all of
the patients were receiving hypoglycemic drug {second genera-
tion of sulfonylurea (Glimepiride tablets 20 mg} + anti-hyper-
glycemic drug {Bigua-nides (Metformin tablets 500 mg)}.
Most of the patients were receiving Vitamin B complex as neu-
rotonic to alleviate the neuropathy complications of diabetes,
and some of the patients were administering aspirin tablets
(300 mg). It is worthy to mention that, the majority of the pa-
tients, about 78%, were suffering from hypertension and tak-
ing antihypertensive drugs.
Also, about 70% of the patients exhibited a family history
of diabetes, many of the patients were suffering from diabetic
complications as neuropathy, (tremors, peripheral numbness,
and cramps), headache, retinopathy (blurred vision and cata-
ract), fatigue, thirst, drowsiness, teeth extraction, joint pain,
severe legs inﬂammations.
During the follow-up of the patients and their counseling it
was found that some of the complications especially joint and
leg pain with neuropathy were highly diminished after DF
administration.
3.2. Serum activities of ALT, AST, ALP and serum
concentrations of urea and creatinine
It is apparent from the results in Table 1 that the administra-
tion of DF for a period of 45 days neither signiﬁcantly change
the activities of ALT, and AST, ALP nor the serum concentra-
tions of urea and creatinine.
3.3. Serum glucose, fructosamine and glycosylated
hemoglobin(HbA1c)
Serum glucose level was signiﬁcantly increased in female dia-
betic patients group A and B reaching 221.92% and
200.60%, respectively, of the value obtained in the control
group. Administration of DF for 45 days in both groups re-
sults in a signiﬁcant decrease of these high levels in such groups
of patients.
Concerning the results of serum fructosamine, its value sig-
niﬁcantly increased in the diabetic patients by 24.34% and
23.15% for groups A and B, respectively, than that of the nor-
mal control group and then decreased upon administration of
Table 1 Clinical characteristics of type 2 diabetic female patients before and after administration of Daﬂon.
Group Alkaline phosphatase (U/L) ALT (U/L) AST (U/L) Urea (mg/dl) Creatinine (mg/dl)
Normal healthy 123.12 ± 10.47 22.5 ± 2.18 19.85 ± 2.45 38.56 ± 2.31 0.91 ± 0.05
Diabetic group (A) before treatment 117.75 ± 10.35 29.91 ± 3.02 23.16 ± 1.32 46.51 ± 5.07 1.1 ± 0.04
Diabetic group (A) after treatment 129.70 ± 11.92 26.56 ± 3.56 25.75 ± 3.06 43.74 ± 3.75 1.03 ± 0.06
Diabetic group (B) before treatment 134.51 ± 12.05 19.76 ± 2.21 26.72 ± 4.32 43.59 ± 2.14 1.19 ± 0.06
Diabetic group (B) after treatment 126.86 ± 9.65 23.49 ± 2.05 23.04 ± 2.23 43.32 ± 3.56 1.23 ± 0.07
Values are expressed as mean ± SE.
Number of patients in group A= 12, and number of patients in group B = 12.
Table 2 Serum glucose, fructosamine and percentage of HbA1c in female diabetic patients before and after administration of Daﬂon
.
Group Glucose (mg/dl) Fructosamine (lmol/L) HbA1c (%)
Normal healthy 87.97 ± 5.79 235.30 ± 7.13 5.78 ± 0.14
Diabetic group (A) before treatment 195.22 ± 7.31a 292.58 ± 8.18a 8.15 ± 0.53a
Diabetic group (A) after treatment 145.25 ± 7.72a,b 259.12 ± 2.54a,b 6.44 ± 0.57a
Diabetic group (B) before treatment 176.47 ± 6.36a 289.78 ± 8.53a 8.16 ± 0.43a
Diabetic group (B) after treatment 143.39 ± 7.06a,b 271.79 ± 6.07a 7.57 ± 0.52a
Values are expressed as mean ± SEM.
Number of patients in group A= 12, number of patients in group B = 12, and number of normal healthy = 12.
a There is a signiﬁcant difference between the mean values of the different variables before and/or after Daﬂon Administration Compared to
the Normal Healthy Group by using ANOVA at p< 0.05.
b There is a signiﬁcant difference between the mean values of the different variables before and after Daﬂon Administration Compared to the
diabetic female patients by using ANOVA at p< 0.05.
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increased the diabetic groups compared to the healthy control
one, while, on DF administration, both groups, showed a non-
signiﬁcant decrease in HbA1c level (Table 2).
3.4. Serum lipid proﬁle
The data presented in Table 3 indicates that total cholesterol
was signiﬁcantly higher in the diabetic groups A and B, reach-
ing to 135.07% and 136.52% of the value obtained in normal
control, respectively. Administration of DF signiﬁcantly de-
creases these values in group A and B by 22.02% and
28.01%, respectively.
Serum HDL–C did not signiﬁcantly differ or changed
among the three studied groups, moreover, LDL–C values
were signiﬁcantly higher in both diabetic groups A and B from
those of control group, besides, this parameter was signiﬁ-Table 3 Lipid proﬁle in female diabetic patients before and after a
Group Total–cholesterol (mg/dl) HDL–
Normal healthy 176.52 ± 12.62 47.39 ±
Diabetic group (A) before treatment 238.43 ± 12.49a 35.12 ±
Diabetic group (A) after treatment 185.93 ± 11.69b 44.48 ±
Diabetic group (B) before treatment 240.99 ± 26.90a 35.98 ±
Diabetic group (B) after treatment 173.49 ± 13.99b 48.82 ±
Values are expressed as mean ± SEM.
Number of patients in group A= 12, number of patients in group B =
a There is a signiﬁcant difference between the mean values of the differe
the Normal Healthy group by using ANOVA at p< 0.05.
b There is a signiﬁcant difference between the mean values of the differe
diabetic female patients by using ANOVA at p< 0.05.cantly lower than the respective values after administration
of DF in both groups.
Serum triglycerides were signiﬁcantly higher in female dia-
betic patients group A and B reaching 264.57% and
206.74%, respectively, of the value obtained in the control
group. Although these values signiﬁcantly decreased in group
A only (P-value <0.05), after DF administration compared
to those before treatment, they were signiﬁcantly higher than
the control ones, in both groups A and B, even after DF treat-
ment (Table 3).
3.5. Blood glutathionne (GSH) and serum protein thiol
The results in Table 4 Blood GSH content was signiﬁcantly de-
creased by 35.59% and 28.86% in groups A and B, respec-
tively, compared to the normal healthy group.
Administration of DF resulted in a signiﬁcant increase indministration of Daﬂon.
cholesterol (mg/dl) LDL–cholesterol (mg/dl) Triglyceride (mg/dl)
4.77 108.90 ± 9.08 101.13 ± 24.36
6.29 150.3 ± 7.26a 267.56 ± 33.07a
4.88 107.45 ± 4.15b 169.28 ± 18.54b
4.83 163.22 ± 7.32a 209.08 ± 15.08a
4.98 89.67 ± 7.98b 175.68 ± 7.49a
12, and number of normal healthy = 12.
nt variables before and/or after Daﬂon Administration Compared to
nt variables before and after Daﬂon Administration Compared to the
Table 4 Blood glutathione (GSH), serum protienthiol (PSH), malondialdehyde (MDA) and nitric oxide (NO) levels in female diabetic
patients before and after Daﬂon administration.
Parameter Normal healthy group Diabetic group A Diabetic group B
Before treatment After treatment Before treatment After treatment
GSH (mg/dl) 22.14 ± 2.36 14.26 ± 0.73a 25.07 ± 1.61b 15.75 ± 0.70a 24.32 ± 1.31b
PSH (gmol/ml) 504.08 ± 32.01 486.31 ± 46.48 509.74 ± 30.49 471.89 ± 41.01 497.71 ± 43.84
MDA (gmol/ml) 0.22 ± 0.02 0.43 ± 0.04a 0.27 ± 0.04b 0.42 ± 0.02a 0.31 ± 0.018a,b
NO (nitrite/nitrate) (gmol/ml) 48.98 ± 4.20 29.78 ± 1.47a 41.74 ± 2.14a,b 24.69 ± 2.04a 35.11 ± 3.87a,b
Values are expressed as mean ± SEM.
Number of patients in group A= 12, number of patients in group B = 12, and number of normal healthy = 12.
a There is a signiﬁcant difference between the mean values of the different variables before and/or after Daﬂon Administration Compared to
the Normal Healthy group by using ANOVA at p< 0.05.
b There is a signiﬁcant difference between the mean values of the different variables before and after Daﬂon Administration Compared to the
diabetic female patients by using ANOVA at p< 0.05.
Table 5 Mean ± serum level of C-reactive protein in diabetic
female patients before and after Daﬂon administration.
Group C-reactive protein (lg/ml)
Normal healthy 2.97 ± 0.75
Diabetic group (A) before treatment 9.01 ± 1.47a
Diabetic group (A) after treatment 5.09 ± 0.51a,b
Diabetic group (B) before treatment 10.12 ± 2.24a
Diabetic group (B) after treatment 6.26 ± 0.58a,b
Values are expressed as mean ± SEM
Number of patients in group A= 12, number of patients in group
B = 12, and number of normal healthy = 12.
a There is a signiﬁcant difference between the mean values of the
different variables before and/or after Daﬂon Administration
Compared to the Normal Healthy group by using ANOVA at
p< 0.05.
b There is a signiﬁcant difference between the mean values of the
different variables before and after Daﬂon Administration Com-
pared to the diabetic female patients by using ANOVA at p< 0.05.
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um protein thiol concentration was not signiﬁcantly changed
among the studied groups.
3.6. Effect on serum nitric oxide (nitrite/nitrate) and
malondialdehyde
The data reported in Table 4 shows that serum nitric oxide val-
ues were signiﬁcantly lower by 39.20% and 49.59% in the dia-
betic groups A and B respectively compared to the normal
healthy group. On DF administration, nitric oxide (nitrite/ni-
trate) values signiﬁcantly increased in both groups, however,
nitric oxide values still signiﬁcantly lower than those of the
control group in patients administered DF only.
Serum MDA levels were signiﬁcantly higher in groups A
and B compared to the control group (0.43 ± 0.04, and
0.42 ± 0.02 versus 0.22 ± 0.02, respectively, P> 0.05), how-
ever these values signiﬁcantly decreased after DF treatment
compared to values obtained before treatment, but still signif-
icantly higher than that of healthy group in patients adminis-
tered DF only.
3.7. Serum C-reactive protein
The results in Table 5 shows that serum C-reactive protein lev-
els in the diabetic groups A and B were signiﬁcantly higher
than that of the normal healthy group. Although these values
signiﬁcantly decreased after DF administration, they remained
signiﬁcantly higher than the normal group values.4. Discussion
Diabetic patients showed an increased mortality and morbidity
compared with non-diabetics and are more likely to develop
cardiovascular diseases (Boemi et al., 1993). This high risk can-
not be completely predicted by known risk factors such as
hypertension and plasma lipids. Serum C-reactive protein
(CRP) is a biomarker for chronic inﬂammation and is a sensi-
tive risk factor for cardiovascular diseases. It is released in re-
sponse to inﬂammatory markers present within atherosclerotic
plaques and may be a stronger predictor of cardiovascular dis-
ease than LDL cholesterol (Ridker et al., 2004; Prasad, 2006).
The present study revealed a highly signiﬁcant increase in ser-um CRP in diabetic female patients compared to non-diabetic
control, suggesting increase in cardiovascular disease risk.
Administration of Daﬂon either alone or with oral hypo-gly-
cemic drug produced signiﬁcant decrease in its level, this
decreasing effect of Daﬂon may be referred to its anti-inﬂam-
matory effect as proved in a model of inﬂammatory granuloma
in rat where Daﬂon 500 mg reduced edema formation and
inhibited the synthesis for prostaglandin E2 (PGE2) and
thromboxane B2 (TXB2) (Jean and Bodinier, 1994). More-
over, diosmin was reported as a potent inhibitor of PGE2
and thromboxane A2 (TxA2) (Labrid, 1994).
The female patients conducted in this study showed highly
levels in serum glucose, fructosamine and HbA1c, indicating
sustained hyperglycemia in these patients. In patients with type
2 diabetes, previous studies have shown an association between
the degree of hyperglycemia and increased risk of microvascu-
lar complications, myocardial infarction (Klein, 1995; Lehto
et al., 1996) and macrovascular mortality (Uusitupa et al.,
1993). The relative risk for myocardial infarction seems to in-
crease with any increase in glycaemia above the normal range
(Fuller et al., 1983), whereas the risk for microvascular disease
is thought to occur only with more extreme concentrations of
glycemia (Jarrett and Keen, 1976).
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diabetic patients resulted in signiﬁcant decrease in serum
glucose level which could be attributed to hesperidin content
in Daﬂon tablets. Jung et al. (2004) found that the improve-
ment in hyperglycemia associated with hesperidin is attrib-
uted to increase in glucose utilization via elevation in
glycolysis and hepatic glycogen concentration and this was
mediated through activation of glucokinase enzyme. Jung
et al. (2006) found that hesperidin signiﬁcantly increased
the glucokinase mRNA level. Although the decrease in
HbA1c in the current study after Daﬂon
 administration is
not signiﬁcant, but it could be promising in decreasing car-
diovascular disease risk. Stratton et al. (2000) stated that each
1% reduction in haemoglobin HbA1c was associated with a
37% decrease in risk for microvascular complica-tions and
a 21% decrease in the risk of any end point or death related
to diabetes.
Several experimental, epidemiologic and clinical studies
support the notation that oxidative stress plays signiﬁcant
role in type 2 diabetes and in the development of cardiovas-
cular diseases (Jacob and Burri, 1996). In the present study,
the increased levels of MDA clearly show that the diabetic
patients were exposed to an increased oxidative stress via li-
pid peroxidation (Mahboob et al., 2005), while decreased le-
vel of glutathione indicates decreased scavenging capacity
against elevated lipid peroxidation process in these patients.
This ﬁnding could be referred to the fact that hyperglycemia
triggers the generation of free radicals and oxidant stress
(Hunt et al., 1990). Hyperglycemia also leads to activation
of sorbitol pathway and contributes to the formation of tri-
ose phosphate which generates oxoaldehydes with high
capacity to produce protein glycation and oxidative stress
(Diaz-Flores et al., 2004). Furthermore, hyperglycemia has
been shown not only to generate ROS, but also inactivate
some of the scavenging enzymes through non-enzymatic gly-
cation (Blakytny and Harding, 1992). Administration of Daf-
lon either alone or with oral hypoglycemic drugs to female
patients with type 2 diabetes showed decrease in serum MDA
with subsequent increase in GSH levels, this ameliorating ef-
fect of Daﬂon could attribute to decrease in the cardiovas-
cular diseases risk. Hesperidin in combination with diosmin
has been shown to inhibit the reactive oxygen radicals pro-
duction in Zymosan-stimulated human polymoorphnuclear
neutrophils (Jean and Bodinier, 1994), it also decreased the
level of TBARS in kidney homogenate of CCl4 treated rats
(Tirkey et al., 2005).
Abnormalities in lipid metabolism often present in patients
with type 2 diabetes (Rosenson, 2005). The current study re-
vealed signiﬁcant elevation in total-cholesterol, LDL–choles-
terol and triglycerides levels in type 2 diabetes female
patients compared to non-diabetic control group (Garvey
et al., 2003). Type 2 diabetes is characterized by increased
secretion of apolipoprotein (apo) B which is a key component
of VLDL assembly process leading to increased serum levels of
triglycerides (Krauss and Siri, 2004; Mayerson et al., 2002).
The increased levels of LDL–cholesterol with concomitant in-
crease in free radicals increase the probability for oxidation of
LDL forming oxidized-LDL which was proposed to stimulate
the expression of adhesion molecules of endothelial cells and
might cause adhesion of blood monocytes to vascular endothe-
lium, the early stage of atherosclerosis (Steinberg, 1995; Stein-
berg et al., 1989).Administration of Daﬂon to type 2 diabetic female pa-
tients resulted in signiﬁcant decrease in total-and LDL–choles-
terol when given either alone or with oral hypoglycemic drugs;
while signiﬁcant decreased in triglyceride level was observed
only in patients administered Daﬂon with oral hypoglycemic
drugs. In support of this results, serum cholesterol decreased
and in vitro activities of hydroxymethylglutaryl-CoA reductase
and sterol O-acyltransferase were inhibited in cholesterol-fed
rats supplemented with mixtures of principal citrus ﬂavonoids
(Bok et al., 1999). Additionally, treatment of HepG2 cells with
hesperetin, a metabolite of hesperidin, reduced the net secre-
tion of apolipoprotein B (apo B), the LDL protein (Borradaile
et al., 1999). This response could provide an additional cardio-
protective effect.
Diosmin could also help in reducing the risk for cardiovas-
cular diseases as it is previously reported to causes a signiﬁcant
decrease in plasma levels of endothelial adhesion molecules,
which increased by ox-LDL, thus providing protection against
microcirculatory damage (Ramelet, 2000).
A decline in NO bioactivity and the resultant endothelial
dysfunction occurs in many disease settings including; hyper-
lipidemia, hypertension, metabolic syndrome, and diabetes
(Mueller et al., 2005). The present study showed a signiﬁcant
decrease in serum NO (nitrite/nitrate) level in the diabetic
group compared to the non-diabetic one. Impairment in the
bioavailability of nitric oxide (NO) results in compromised
vasodilatation with subsequent increase in the cardiovascular
risk (Endemann and Schiffrin, 2004). Both endothelium-de-
rived and platelet-derived NO contribute to preventing platelet
adhesion to the vascular wall and platelet aggregation, there-
fore playing a key role in the prevention of thrombus forma-
tion, which is a major trigger of coronary accidents (Le
Melle´do et al., 2004). The decrease in NO (nitrite/nitrate) level
is observed in the current study may be correlated to the hyper-
glycemia recorded in such patients (Williams et al., 1998). High
glucose-induced NO deﬁciency is partially attributable to the
uncoupling of the endothelial NO synthase (eNOs) reaction
resulting in the net synthesis of superoxide and to the oxidative
inactivation of NO (Hayden and Tyagi, 2003; Wadham et al.,
2007). Considerable evidence indicates that atherogenic oxi-
dized low-density lipoprotein (ox-LDL) may impair signal
transduction activation of nitric oxide synthase enzyme
(NOs), thus diminishing the synthesis of NO (Liao et al.,
1995). In addition, CRP at concentrations known to predict
CVD has been found to down regulate eNOs and destabilize
eNOs mRNA, with resultant decreases in both basal and stim-
ulated NO release (Ja¨rvisalo et al., 2002). Daﬂon administra-
tion in the current study revealed a signiﬁcant increase in
serum NO (nitrite/nitrate) level attributed to its hypoglycemic
and hypolipidemic effect. Increase in NO (nitrite/nitrate) level
by Daﬂon treatment could decrease the risk for cardiovascu-
lar disease.5. Conclusion
Administration of Daﬂon as a co-therapy with oral hypogly-
cemic drugs to patients with type 2 diabetes might be decrease
the incidence for cardiovascular diseases, which evidenced by
decrease in CRP level. Such decrease in the cardiovascular dis-
ease risk could be attributed to its hypoglycemic, anti-oxida-
tive stress, hypolipidemic effects with concomitant increase in
Evaluation of clinical activity and safety of Daﬂon 500 mg in type 2 diabetic female patients 205NO level. Further clinical trials are essential for strengthening
the evidence base on the role of this drug in the cardiovascular
risk in diabetic patients.Acknowledgements
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